Aditya Birla Sun Life Pharma and Healthcare Fund vs Nippon India Pharma Fund: portfolio overlap
In Oct 2026, 29 stocks were in both portfolios, and the two overlap 65.8% by weight. A comparison, not advice.
Overlap65.8%by weight, Oct 2026
Stocks in common29held by both
Stocks held40 · 37Aditya Birla Sun Life Pharma and Healthcare Fund · Nippon India Pharma Fund
Aditya Birla Sun Life Pharma and Healthcare Fund and Nippon India Pharma Fund: stocks in common
How this is counted
Overlap = for every stock both hold, the smaller of its two weights, added up (as in the scheme finder's compare). Largest shared weight first.
Only in Aditya Birla Sun Life Pharma and Healthcare Fund
Only in Nippon India Pharma Fund
| Stock | % of net assets |
|---|---|
| MEDPLUS MedPlus Health Services Limited | 2.26% |
| NH Narayana Hrudayalaya Limited | 1.56% |
| AKUMS Akums Drugs and Pharmaceuticals Limited | 1.09% |
| SANOFI Sanofi India Limited | 1.06% |
| MOLBIO Molbio Diagnostics Limited | 0.53% |
| ASTRAZEN AstraZeneca Pharma India Limited | 0.46% |
| INDOCO Indoco Remedies Limited | 0.38% |
| CONCORDBIO Concord Biotech Limited | 0.15% |
Side by side, as filed
| Fact | Aditya Birla Sun Life Pharma and Healthcare Fund | Nippon India Pharma Fund |
|---|---|---|
| Fund house | Aditya Birla Sun Life Mutual Fund | Nippon India Mutual Fund |
| AMFI category | Equity Scheme - Sectoral/ Thematic | Equity Schemes - Sectoral Fund |
| Equity held Oct 2026 | ₹1,082 cr | ₹9,051 cr |
| Equity, % of fund Oct 2026 | 99.4% | 99.6% |
| Stocks held Oct 2026 | 40 | 37 |
| AUM average, July - September 2026 | ₹1,076 cr | ₹9,272 cr |
| Total expense ratio, direct | 1.04 % as of 12 Nov 2026 | 0.98 % as of 13 Nov 2026 |
| Return 1 year 13 Nov 2025 to 13 Nov 2026 | +19.66 % in total | +14.10 % in total |
| Return 3 years 13 Nov 2023 to 13 Nov 2026 | +20.69 % a year | +18.54 % a year |
| Return 5 years 12 Nov 2021 to 13 Nov 2026 | +15.87 % a year | +15.24 % a year |
How this is counted
Category as AMFI lists it; AUM = AMFI's average AUM for the quarter; TER = the direct plan's total expense ratio on the date shown; returns = change in NAV between the two dates shown. Past performance may not be sustained in future.
Mutual fund investments are subject to market risks; read all scheme related documents carefully.